RGS10 and Parkinson disease: Correcting for age and sex, we found a significant main effect of patient group (COHORT) on levels of RGS10 in the CSF (Supplemental Fig. 1A), with post-hoc analysis identifying a significant decrease in RGS10 levels of PD patients compared to healthy controls and prodromal individuals (1% decrease) with no difference between prodromal individuals and healthy controls (Fig. 1B).